Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy

He,Jin-Hua; Liao,Xiao-Li; Wang,Wei; Li,Dan-Dan; Chen,Wen-Dan; Deng,Rong; Yang,Dajun; Han,Ze-Ping; Jiang,Jian-Wei; Zhu,Xiao-Feng

doi:10.3892/ijo.2014.2497

Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy

Authors:
- Jin-Hua He
- Xiao-Li Liao
- Wei Wang
- Dan-Dan Li
- Wen-Dan Chen
- Rong Deng
- Dajun Yang
- Ze-Ping Han
- Jian-Wei Jiang
- Xiao-Feng Zhu
View Affiliations

Affiliations: Department of Laboratory, Central Hospital of Panyu, Guangzhou, Guangdong, P.R. China, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China, Department of Biochemistry, Medical College, Jinan University, Guangzhou, Guangdong, P.R. China, Ascenta Therapeutics Incorporation, Malvern, PA 19355, USA
Published online on: June 11, 2014 https://doi.org/10.3892/ijo.2014.2497
Pages: 1099-1108

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a major cause of cancer deaths. Concurrent administration of radiation and chemotherapy is the treatment of choice for advanced NPC. Previously, we showed that apogossypolone (ApoG2) induced apoptosis by blocking the binding of Bcl-2 to Bax, arresting the cell cycle in the S phase, in turn inhibiting proliferation of NPC cells both in vitro and in vivo. In the present study, we showed that ApoG2 inhibited the proliferation of NPC cells in a dose-dependent manner. We treated CNE1, CNE2 and SUNE1 cells with ApoG2 for 72 h, and calculated the IC50 values as 2.84, 5.64 and 2.18 µM, respectively. Normal NP69 cell proliferation was not significantly inhibited. ApoG2 treatment induced significant autophagy, demonstrated by an increase in LC3-II protein expression, reduced protein p62 expression, and accumulation of punctuate GFP-LC3 in the cytoplasm of CNE1 or CNE2 cells. Sh-Atg5 attenuated the autophagy induced by ApoG2, indicating that Atg5 was required for ApoG2-induced autophagy. In addition, ApoG2 treatment blocked the binding of Bcl-2 to Beclin 1 protein, releasing pro-autophagic Beclin 1, which in turn triggered the autophagic cascade. Colony formation assays indicated that ApoG2 enhanced radiosensitization of CNE2 cells. In the ApoG2-plus-radiation combination group, more ring-shaped structures were evident in CNE1 and CNE2 cultures. LC3-II expression was enhanced and that of p62 reduced, compared to the ApoG2-only, radiation-only and control groups. ApoG2 enhanced the radiosensitivity of CNE2 xenografts in nude mice as measured by (C-T)/C ratios (as percentages); the values for the ApoG2 and radiation groups were 46.89% and 19.34%, respectively. The ApoG2-plus-radiation group exhibited greater antitumor activity (the inhibitory rate was 61.64%). Immunohistological staining showed that LC3-II expression became gradually upregulated in the ApoG2-plus-radiation group. Together, the results suggest that ApoG2 inhibits the binding of Bcl-2 to Beclin 1, inducing autophagy and radiosensitizing NPC cells both in vitro and in vivo.

View Figures

View References

1	McDermott AL, Dutt SN and Watkinson JC: The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 26:82–92. 2001. View Article : Google Scholar : PubMed/NCBI
2	Bei JX, Jia WH and Zeng YX: Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin Cancer Biol. 22:96–106. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol. 22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
4	Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S and Endo K: Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx. 39:137–144. 2012. View Article : Google Scholar
5	Kang MH and Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zhou FF, Yang Y and Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 278:403–413. 2011. View Article : Google Scholar : PubMed/NCBI
7	Levine B, Sinha S and Kroemer G: Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI
8	Green DR and Evan GI: A matter of life and death. Cancer Cell. 1:19–30. 2002. View Article : Google Scholar
9	Lu QL, Elia G, Lucas S and Thomas JA: Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer. 53:29–35. 1993. View Article : Google Scholar : PubMed/NCBI
10	Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY, Zhang WL, Tan C, Li XL, Shen SR, Zhou M, Zhang QH and Ou YJ: Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol. 37:593–605. 2006. View Article : Google Scholar
11	Sheu LF, Chen A, Meng CL, Ho KC, Lin FG and Lee WH: Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia, and nasopharyngeal carcinoma: association with p53 expression. Hum Pathol. 28:556–562. 1997. View Article : Google Scholar
12	Yu Y, Dong W, Li X, Yu E, Zhou X and Li S: Significance of c-Myc and Bcl-2 protein expression in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 129:1322–1326. 2003. View Article : Google Scholar : PubMed/NCBI
13	Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D and Zeng YX: ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer. 123:2418–2429. 2008. View Article : Google Scholar
14	Del Poeta G, Venditti A, Del Principe MI, et al: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 101:2125–2131. 2003.PubMed/NCBI
15	Minn AJ, Rudin CM, Boise LH and Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 86:1903–1910. 1995.PubMed/NCBI
16	Yoshino T, Shiina H, Urakami S, et al: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 12:6116–6124. 2006. View Article : Google Scholar : PubMed/NCBI
17	Lacy J, Loomis R, Grill S, Srimatkandada P, Carbone R and Cheng YC: Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV1 nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer. 119:309–316. 2006. View Article : Google Scholar : PubMed/NCBI
18	Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK and Kitada S: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kang MH, Wan Z, Kang Y, Sposto R and Reynolds CP: Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1inactivation. J Natl Cancer Inst. 100:580–595. 2008. View Article : Google Scholar : PubMed/NCBI
20	Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388. 2006. View Article : Google Scholar : PubMed/NCBI
21	Chauhan D, Velankar M, Brahmandam M, et al: A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 26:2374–2380. 2006. View Article : Google Scholar : PubMed/NCBI
22	Van Delft MF, Wei AH, Mason KD, et al: The BH3 efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 10:389–399. 2006.PubMed/NCBI
23	Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD and Letai A: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 117:112–121. 2007.PubMed/NCBI
24	Lin X, Morgan-Lappe S and Huang X: ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitorABT-737. Oncogene. 26:3972–3979. 2007.
25	Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN and Rudin CM: Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 68:2321–2328. 2008. View Article : Google Scholar : PubMed/NCBI
26	MacVicar GR, Kuzel TM and Curti BD: An open label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC). J Clin Oncol. 26:160482008.
27	Yang D, Chen J, Xu L, Gao W, Guo J, Qiu S, Holmlund J, Sorensen M and Wang S: AT-101 and ApoG2, highly potent and orally active small molecule inhibitors of Mcl-1 protein and potential application for apoptosis-targeted anticancer therapy. AACR-NCI-EORCT International Conference on Molecular Targets and Cancer Therapeutics; pp. 255abs. 223. Nov 14–18 2005; http://www.aacr.org/Uploads/DocumentRepository/pdf_files/2005MTCT/MT05_abstracts_C.pdf.
28	Arnold AA, Aboukameel A, Chen J, Yang D and Wang S: Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Mol Cancer. 7:202008. View Article : Google Scholar : PubMed/NCBI
29	Dao VT, Dowd MK, Martin MT, Gaspard C, Mayer M and Michelot RJ: Cytotoxicity of enantiomers of gossypol Schiff’s bases and optical stability of gossypolone. Eur J Med Chem. 39:619–624. 2004.PubMed/NCBI
30	Sun J, Li ZM, Hu ZY, Lin XB, Zhou NN, Xian LJ, Yang DJ and Jiang WQ: ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells. Anticancer Drugs. 19:967–974. 2008. View Article : Google Scholar : PubMed/NCBI
31	Zhang XQ, Huang XF, Hu XB, Zhan YH, An QX, Yang SM, Xia AJ, Yi J, Chen R, Mu SJ and Wu DC: Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. Asian J Androl. 12:697–708. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hu ZY, Sun J, Zhu XF, Yang D and Zeng YX: ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. J Transl Med. 7:742009. View Article : Google Scholar : PubMed/NCBI
33	Zhou WJ, Deng R, Zhang XY, Feng GK, Gu LQ and Zhu XF: G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther. 8:3203–3213. 2009. View Article : Google Scholar : PubMed/NCBI
34	Adams R, Morris RC, Geissman TA, et al: Structure of gossypol. XV An interpretation of its reactions. J Am Chem Soc. 60:21931938. View Article : Google Scholar
35	Tanida I, Ueno T and Kominami E: LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 36:2503–2518. 2004. View Article : Google Scholar : PubMed/NCBI
36	Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G and Johansen T: p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 282:24131–24145. 2007. View Article : Google Scholar : PubMed/NCBI
37	Pyo JO, Nah J, Kim HJ, Lee HJ, Heo J and Lee H: Compensatory activation of ERK1/2 inAtg5-deficient mouse embryo fibroblasts suppresses oxidative stress-induced cell death. Autophagy. 4:315–321. 2008. View Article : Google Scholar : PubMed/NCBI
38	Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N and Hickman JA: BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/ Bcl-X(L). Autophagy. 3:374–376. 2007. View Article : Google Scholar
39	Gao P, Bauvy C, Souquère S, Tonelli G, Liu L, Zhu Y, Qiao Z, Bakula D, Proikas-Cezanne T, Pierron G, Codogno P, Chen Q and Mehrpour M: The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem. 285:25570–25581. 2010. View Article : Google Scholar : PubMed/NCBI
40	Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K and Tavernarakis N: Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 26:2527–2539. 2007. View Article : Google Scholar : PubMed/NCBI
41	Bjørkøy G, Lamark T and Brech A: p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 171:603–614. 2005.PubMed/NCBI
42	Boland B and Nixon RA: Neuronal macroautophagy: from development to degeneration. Mol Aspects Med. 27:503–519. 2006. View Article : Google Scholar
43	Lian J, Wu X, He F, Karnak D, Tang W, Meng Y, Xiang D, Ji M, Lawrence TS and Xu L: A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ. 8:60–71. 2011. View Article : Google Scholar : PubMed/NCBI
44	Pattingre S, Tassa A, Qu X, et al: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 122:927–939. 2005. View Article : Google Scholar : PubMed/NCBI